Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-07-06

FDA Approved: LEQEMBI — Supplemental Application (Eisai Inc.)

View source ↗

Summary

FDA approved a supplemental application for LEQEMBI (lecanemab) from Eisai Inc., indicating a regulatory action related to the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LEQEMBI (lecanemab)

Snippet

SUPPL AP for LEQEMBI (LECANEMAB)